PURPOSE: Lymph node status is an important predictor of survival in pancreatic cancer. We performed a secondary analysis of Radiation Therapy Oncology Group (RTOG) 9704, an adjuvant chemotherapy and chemoradiation trial, to determine the influence of lymph node factors--number of positive nodes (NPN), total nodes examined (TNE), and lymph node ratio (LNR ratio of NPN to TNE)--on OS and disease-free survival (DFS). PATIENT AND METHODS: Eligible patients from RTOG 9704 form the basis of this secondary analysis of lymph node parameters. Actuarial estimates for OS and DFS were calculated using Kaplan-Meier methods. Cox proportional hazards models were performed to evaluate associations of NPN, TNE, and LNR with OS and DFS. Multivariate Cox proportional hazards models were also performed. RESULTS: There were 538 patients enrolled in the RTOG 9704 trial. Of these, 445 patients were eligible with lymph nodes removed. Overall median NPN was 1 (min-max, 0-18). Increased NPN was associated with worse OS (HR=1.06, p=0.001) and DFS (HR=1.05, p=0.01). In multivariate analyses, both NPN and TNE were associated with OS and DFS. TNE>12, and >15 were associated with increased OS for all patients, but not for node-negative patients (n=142). Increased LNR was associated with worse OS (HR=1.01, p<0.0001) and DFS (HR=1.006, p=0.002). CONCLUSION: In patients who undergo surgical resection followed by adjuvant chemoradiation, TNE, NPN, and LNR are associated with OS and DFS. This secondary analysis of a prospective, cooperative group trial supports the influence of these lymph node parameters on outcomes after surgery and adjuvant therapy using contemporary techniques.
RCT Entities:
PURPOSE: Lymph node status is an important predictor of survival in pancreatic cancer. We performed a secondary analysis of Radiation Therapy Oncology Group (RTOG) 9704, an adjuvant chemotherapy and chemoradiation trial, to determine the influence of lymph node factors--number of positive nodes (NPN), total nodes examined (TNE), and lymph node ratio (LNR ratio of NPN to TNE)--on OS and disease-free survival (DFS). PATIENT AND METHODS: Eligible patients from RTOG 9704 form the basis of this secondary analysis of lymph node parameters. Actuarial estimates for OS and DFS were calculated using Kaplan-Meier methods. Cox proportional hazards models were performed to evaluate associations of NPN, TNE, and LNR with OS and DFS. Multivariate Cox proportional hazards models were also performed. RESULTS: There were 538 patients enrolled in the RTOG 9704 trial. Of these, 445 patients were eligible with lymph nodes removed. Overall median NPN was 1 (min-max, 0-18). Increased NPN was associated with worse OS (HR=1.06, p=0.001) and DFS (HR=1.05, p=0.01). In multivariate analyses, both NPN and TNE were associated with OS and DFS. TNE>12, and >15 were associated with increased OS for all patients, but not for node-negative patients (n=142). Increased LNR was associated with worse OS (HR=1.01, p<0.0001) and DFS (HR=1.006, p=0.002). CONCLUSION: In patients who undergo surgical resection followed by adjuvant chemoradiation, TNE, NPN, and LNR are associated with OS and DFS. This secondary analysis of a prospective, cooperative group trial supports the influence of these lymph node parameters on outcomes after surgery and adjuvant therapy using contemporary techniques.
Authors: T A Sohn; C J Yeo; J L Cameron; L Koniaris; S Kaushal; R A Abrams; P K Sauter; J Coleman; R H Hruban; K D Lillemoe Journal: J Gastrointest Surg Date: 2000 Nov-Dec Impact factor: 3.452
Authors: Sean P Cleary; Robert Gryfe; Maha Guindi; Paul Greig; Lloyd Smith; Robert Mackenzie; Steven Strasberg; Sherif Hanna; Bryce Taylor; Bernard Langer; Steven Gallinger Journal: J Am Coll Surg Date: 2004-05 Impact factor: 6.113
Authors: M L Foo; L L Gunderson; D M Nagorney; D C McLlrath; J A van Heerden; J S Robinow; L K Kvols; G R Garton; J A Martenson; S S Cha Journal: Int J Radiat Oncol Biol Phys Date: 1993-06-15 Impact factor: 7.038
Authors: John P Neoptolemos; Deborah D Stocken; Helmut Friess; Claudio Bassi; Janet A Dunn; Helen Hickey; Hans Beger; Laureano Fernandez-Cruz; Christos Dervenis; François Lacaine; Massimo Falconi; Paolo Pederzoli; Akos Pap; David Spooner; David J Kerr; Markus W Büchler Journal: N Engl J Med Date: 2004-03-18 Impact factor: 91.245
Authors: Shahid G Farid; Gavin A Falk; Daniel Joyce; Sricharan Chalikonda; R Matthew Walsh; Andrew M Smith; Gareth Morris-Stiff Journal: HPB (Oxford) Date: 2012-11-19 Impact factor: 3.647
Authors: Andrew M McDonald; Caleb R Dulaney; Javier López-Araujo; James A Posey; Kimberly S Keene; John D Christein; Martin J Heslin; Tina E Wood; Rojymon Jacob Journal: J Gastrointest Cancer Date: 2015-06
Authors: Laurice K Fischer; Matthew H Katz; Sun M Lee; Li Liu; Hua Wang; Gauri R Varadhachary; Robert A Wolff; Jeffrey E Lee; Anirban Maitra; Christina L Roland; Jason B Fleming; Jeannelyn Estrella; Asif Rashid; Huamin Wang Journal: Histopathology Date: 2015-06-19 Impact factor: 5.087
Authors: Toshiro Masuda; Amanda M Dann; Irmina A Elliott; Hideo Baba; Stephen Kim; Alireza Sedarat; V Raman Muthusamy; Mark D Girgis; O Joe Hines; Howard A Reber; Timothy R Donahue Journal: J Gastrointest Surg Date: 2017-10-17 Impact factor: 3.452
Authors: Richard Y Lee; Romaine C Nichols; Soon N Huh; Meng W Ho; Zuofeng Li; Robert Zaiden; Ziad T Awad; Bestoun Ahmed; Bradfors S Hoppe Journal: J Gastrointest Oncol Date: 2013-12
Authors: Krisha J Opfermann; Amy E Wahlquist; Elizabeth Garrett-Mayer; Ravi Shridhar; Leander Cannick; David T Marshall Journal: Am J Clin Oncol Date: 2014-04 Impact factor: 2.339